Rubius Therapeutics, Inc.
ARTIFICIAL ANTIGEN PRESENTING CELLS INCLUDING HLA-E AND HLA-G MOLECULES AND METHODS OF USE

Abstract:

The present disclosure relates to artificial antigen presenting cells (aAPCs), in particular engineered erythroid cells and enucleated cells (e.g., enucleated erythroid cells and platelets), that are engineered to include exogenous-antigen presenting polypeptides comprising either HLA-E or HLA-G polypeptides, which may be used to activate or suppress certain immune cells.